Obermeyer B D, Bergstrom R F, Callaghan J T, Knadler M P, Golichowski A, Rubin A
Lilly Research Laboratories, Eli Lilly and Company, Wishard Memorial Hospital, Indianapolis, IN 46202.
Clin Pharmacol Ther. 1990 Jun;47(6):724-30. doi: 10.1038/clpt.1990.100.
Disposition of the H2-receptor antagonist nizatidine was studied in serum, urine, and breast milk. Five lactating women and five nonlactating women participated; the disposition of nizatidine was studied in three of the lactating women. Single and multiple doses of 150 mg nizatidine were administered orally. The disposition of nizatidine (half-life, 1 1/2 hours; apparent serum clearance, 40 L/hr; renal clearance, 27 L/hr; and apparent volume of distribution, 1.4 L/kg) was similar in lactating and nonlactating women. These pharmacokinetic results were analogous to observations for men in other studies. Nizatidine breast milk concentrations were directly proportional to corresponding serum concentrations. On average, 96 micrograms nizatidine, less than 0.1% of the maternal dose, was secreted into milk during a 12-hour interval after either single or multiple doses.
在血清、尿液和母乳中研究了H2受体拮抗剂尼扎替丁的处置情况。五名哺乳期妇女和五名非哺乳期妇女参与了研究；在三名哺乳期妇女中研究了尼扎替丁的处置情况。口服给予单次和多次150毫克尼扎替丁。哺乳期和非哺乳期妇女中尼扎替丁的处置情况（半衰期为1.5小时；表观血清清除率为40升/小时；肾脏清除率为27升/小时；表观分布容积为1.4升/千克）相似。这些药代动力学结果与其他研究中男性的观察结果相似。尼扎替丁在母乳中的浓度与相应的血清浓度成正比。平均而言，单次或多次给药后12小时内，有96微克尼扎替丁（不到母体剂量的0.1%）分泌到乳汁中。
